Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

14-12-09	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
14-12-09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

14-12-09	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
14-12-09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
14-12-09	Merck : to take on superbugs with Cubist Pharma buy	RE
14-12-08	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
14-12-08	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
14-12-08	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
14-12-05	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
13-05-20	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

15-01-13	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
14-12-19	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
14-12-15	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company	PR
14-12-12	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
14-12-12	Cubist Pharmaceuticals : CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.	BU

14-12-21	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
14-12-20	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
14-12-09	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
14-12-08	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
14-12-08	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	1996-12-31

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	2006-08-31
Kenneth J. Martin BRD	Director/Board Member	72	2013-09-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	+4.73%	+3.38%	+19.53%	-8.89%	66.56B
UCB	-1.93%	+0.39%	+58.62%	+226.33%	56.51B
SAMSUNG BIOLOGICS CO.,LTD.	+1.07%	+42.10%	+42.10%	+42.10%	42.98B
CSL LIMITED	+3.45%	+6.04%	-49.46%	-55.91%	40.46B
BIOGEN INC.	+3.04%	+0.04%	+62.66%	-24.29%	31.91B
MODERNA, INC.	+10.01%	+18.57%	+161.59%	-34.48%	31.65B
INCYTE CORPORATION	+2.68%	+2.73%	+70.72%	+88.24%	23.35B
INNOVENT BIOLOGICS, INC.	+2.87%	+16.83%	+3.78%	+192.67%	19.46B
SWEDISH ORPHAN BIOVITRUM AB	-0.13%	+2.75%	+67.48%	+130.07%	17.18B
Average	+2.87%	+8.76%	+48.56%	+61.76%	36.67B
Weighted average by Cap.	+2.79%	+7.31%	+43.69%	+54.30%